30 June 2022 - Revlimid maintenance therapy to treat multiple myeloma passed the health insurance review agency’s reimbursement review four years after winning the license in Korea.

The review committee also expanded the reimbursement criteria for immunotherapy Opdivo (nivolumab), which obtained broadened indication to be used in combination with chemotherapy as the first-line treatment for advanced gastric cancer in June last year.

Read Korea Biomedical Review article